New eTMF module integrates with Enlighten Clinical Solutions’ platform to support inspection-ready clinical trial documentation and execution. ATLANTA, GA, UNITED ...
At FDA's request, Type D Meeting expected in March 2026 to review Comparative Oncology biomarker data from patients treated in OST-HER2 Phase 2b human clinical trial and OST-HER2 trial in spontaneous ...
ATLANTA, Feb. 2, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the presentation of new clinical data from ...
Greetings and welcome to PolyPid's Fourth Quarter and Full Year 2025 Conference Call. [Operator Instructions] As a reminder, this call is recorded. And I would now like to introduce your host for ...
In today’s digital world, audio content has become a crucial element of communication, learning, and entertainment. Podcasts, video narrations, online courses, and voice assistants all rely on voice ...
PolyPid reported a quarterly loss of $0.41 per share for Q4 2025, falling short of the expected loss of $0.33 per share. This resulted in a negative surprise of 24.24%, reflecting challenges in the ...
Request for FDA Rolling Review submitted to FDA on January 30, 2026 Non-Clinical and CMC BLA modules submitted to FDA At FDA's request, Type D Meeting expected in March 2026 to review Comparative ...
Questions? Learn more about RF Study Card Programs by contacting [email protected] and about card programs by contacting [email protected]. Contact Valerie Dennis, Director of ...
1-Year Data from Endospan's NEXUS TRIOMPHE IDE Trial Demonstrate High Patient Survival with Low Morbidity 2-Year Data from the AMDS PERSEVERE IDE Trial Further Demonstrate the Persistent Clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results